By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Expression Pathology said today that Roche will use its Liquid Tissue - SRM technology to identify molecular markers as part of its oncology drug programs.

The Rockville, Md.-based company said that it will provide Roche with multiplexed quantitative assays of cancer signaling pathway proteins and support their activation in formalin-fixed, paraffin-embedded samples for mass spectrometry analysis.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

Aug
23
Sponsored by
Tecan

This webinar will discuss an automated, high-throughput method of generating high-quality antigens and antibodies.